Ocuphire Pharma Inc (OCUP)

NASDAQ
5.56
+0.13(+2.39%)
After Hours
5.61
+0.05(+0.899%)
- Real-time Data
  • Volume:
    380,778
  • Bid/Ask:
    5.56/5.72
  • Day's Range:
    5.35 - 5.64

OCUP Overview

Prev. Close
5.43
Day's Range
5.35-5.64
Revenue
-
Open
5.46
52 wk Range
3.68-14.8
EPS
-8.27
Volume
380,778
Market Cap
68.22M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
551,980
P/E Ratio
-
Beta
0.43
1-Year Change
-46.76%
Shares Outstanding
12,563,989
Next Earnings Date
Aug 04, 2021
What is your sentiment on Ocuphire Pharma Inc?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell

Ocuphire Pharma Inc Company Profile

Ocuphire Pharma Inc Company Profile

Industry
Major Drugs
Employees
5

Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of eye disorders. Its pipeline includes two small-molecule product candidates targeting front and back of the eye indications. The Company’s lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. Nyxol is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Its second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME).

Read More
  • I like $12. Holding until then at least. Good company.
    0
    • Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
      1
      • Any target price?
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.